Home Views Regulator's column

What Nominating Committees should consider for disclosures on investigations

Tan Boon Gin
Tan Boon Gin12/13/2021 10:46 AM GMT+08  • 7 min read
What Nominating Committees should consider for disclosures on investigations
The foremost question whenever a director is under investigation is: Should the director continue to serve on the board?
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Reports of directors of listed issuers being called in for questioning by police investigators surface every now and then. SGX RegCo is often asked following such reports, whether these directors should be allowed to continue to serve on boards or resume their duties in the listed companies.

Nominating Committee’s obligations.

Board directors have fiduciary duties to act in the best interests of the company. Under Rule 720(1), issuers must ensure under Mainboard Rule 210(5)(b) or the equivalent Catalist Rule that directors comply with the character and integrity requirements on a continuing basis.

It is the responsibility of the company’s Nominating Committee (NC) to disclose its independent assessment on the continued appointment of the director in compliance with Rule 720(1) read with Rule 210(5)(b) (or the equivalent Catalist rules). This must be done via an announcement on SGXNet or the company’s annual report and Notice of AGM when the director is up for re-election.

When a director, or Board is under investigation, the NC must rigorously satisfy itself as to whether the allegations against the directors and conditions or restrictions imposed by the regulatory authority or government agency, would cast any doubt on their suitability or continuing ability to act as directors; or more crucially, affect shareholders’ confidence in the company. The NC should also consider whether any measures need to be undertaken to safeguard against risks associated with the directors’ continued appointment.

Debunking two common myths

See also: Live engagement and voting expected at all AGMs for FYs ending 30 June 2022 or after

The foremost question in the minds of stakeholders (particularly shareholders) whenever a director is under investigation is: Should the director continue to serve on the board?

Yet NCs in such a situation sometimes think they are straitjacketed by two things, which we want to emphasise are myths.

The first myth is that the NC cannot do anything while the director is under investigation because this would be pre-judging. The argument is that the individual has not been charged, or convicted; even if he/she was, an appeal may be mounted.

See also: Regulator’s Column: Duties of directors under the Listing Rules

The second is that the NC must stand by a fellow director in a time of crisis as a sign of support.

Instead of considering these myths, the NC should ask itself whether it is in the best interest of the company and the shareholders for the director to remain on the board while an investigation is ongoing.

The NC should also monitor material developments relating to the investigation or require the director concerned to update on material developments.

This will enable the NC to continue to consider the developments and assess the director’s suitability and demonstrate compliance with the character and integrity limbs of Rule 720(5) read with Rule 210(5)(b), if necessary, via SGXNet.

There are three typical scenarios when an investigation gets underway, namely, the entire board is under investigation; a director is investigated for an offence involving the company, and a director is investigated for an offence not involving the company. Regardless of the scenario, the touchstone for NCs should be: Is any decision, disclosure, action or non-action in the best interest of the company and the shareholders?

Scenario 1: The entire board is under investigation.

If this happens, it is almost certain that the investigation involves the company.

Sink your teeth into in-depth insights from our contributors, and dive into financial and economic trends

Some questions for the NC are:

1. Does or will the fact that the entire board is under investigation impact investor confidence in the company?

2. If the entire board is under investigation for disclosure offences, will this affect investor confidence in the timeliness and accuracy of the company’s announcements.

3. Should the NC consider appointing one or two new independent directors (IDs) to the board to give investors confidence that the board is now subject to additional checks and balances? We understand that in such a situation, the resignation of the entire board may not be practical.

4. To further shore up investor confidence, should the NC consider designating one of the incoming IDs as a Lead ID?

5. In terms of the search process for the new incoming IDs, should the NC seek the help of an external party, such as a professional search firm, the Singapore Institute of Directors or perhaps the Securities Investors Association (Singapore)? This is again aimed at giving investors’ confidence in the independence of the new IDs.

6. If doubts on the integrity of the investigative process persist, should the new IDs form a special committee to oversee the investigative process? This may assure the market that the company is cooperating fully in the investigative process and is not being impeded or influenced in any way by the board.

Scenario 2: A director is being investigated for an offence involving the company.

1. What is the director being investigated for?

2. If the investigations point to potential wrongdoing or misconduct by the director or impropriety in the Company’s affairs, how can investors’ confidence in the company and shareholders’ interest be protected if the director remains on the board?

3. Should a special committee be appointed to oversee the investigation or the matters of concern?

4. Should an independent law firm or audit firm be appointed to conduct expedient reviews on the adequacy and effectiveness of the company’s internal controls and recommend enhanced approval processes or measures in the interim?

5. Should there be any Chinese Walls or changes to reporting lines to ensure the integrity of investigations?

6. Should there be additional checks and balances on the director’s power and authority, particularly for executive directors

7. Will the company’s reputation and investors’ confidence in the company be affected if the director remains on the board?

8. Is the board taking the position that the acts were unauthorized?

9. Is the board seeking legal advice and reserving its rights against the director?

10. Is the board instructing counsel?

11. Will any of these things make it difficult for the board to continue to be a well-functioning board?

Scenario 3: A director is being investigated for something that does not involve the company.

1. Will the director be able to dedicate sufficient time if he remains ow much of a distraction will the director cause by remaining on the board while the investigation is ongoing?

2. How much of a distraction will it be from the important business of the company?

3. What is the reputational impact to the company?


The questions listed here are not meant to be exhaustive but are aimed at helping address these crucial points. They are difficult questions and require judgment and robust decision-making by the NC. Nevertheless, NCs cannot be hampered by the two myths above.

In conclusion, the critical issue is not whether the director will be convicted or acquitted, nor what is best for him/her. Rather, the focus of the NC and the board should be on charting a course for the best of the company and its shareholders.

Furthermore, if the NC chooses to retain the directors during the period of the investigation, the NC must ensure that the directors continue to provide updates on material developments related to the investigations. The company is after all subject to the continuing obligation of ensuring that its directors possess the character and integrity required under the listing rules.

Tan Boon Gin is CEO of SGX RegCo

Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.